TY  - JOUR
AU  - García Goñi, Manuel
AU  - Río-Álvarez, Isabel
AU  - Carcedo, David
AU  - Villacampa, Alba
PY  - 2021
DO  - 10.3390/ph14040348
SN  - 1424-8247
UR  - https://hdl.handle.net/20.500.14352/7362
T2  - Pharmaceuticals
AB  - Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System...
LA  - eng
M2  - 348
PB  - MDPI
KW  - Biologics
KW  - Biosimilars
KW  - Budget impact analysis
KW  - Savings
KW  - Pharmaceutical spending
KW  - Cost containment
KW  - Spain.
TI  - Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
TY  - journal article
VL  - 14
ER  -